This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Opicapone oral

Updated 2 Feb 2023 | Other dopaminergic drugs

Presentation

Oral formulations of opicapone.

Drugs List

  • ONGENTYS 50mg capsules
  • opicapone 50mg capsules
  • Therapeutic Indications

    Uses

    Parkinson's disease - adjunct to levodopa + dopa-decarboxylase inhibitor

    Dosage

    Adults

    50mg once daily at bedtime at least one hour before or after levodopa combinations.

    Additional Dosage Information

    Missed doses
    If a dose is missed, the next dose should be taken as scheduled. The patient should not take an extra dose to make up for the missed dose.

    Opicapone enhances the effects of levodopa. To reduce levodopa-related dopaminergic adverse reactions it is often necessary to adjust the daily dose of levodopa by extending the dosing intervals and/or reducing the amount of levodopa per dose within the first days to first weeks after initiating treatment with opicapone, according to the clinical condition of the patient.

    Contraindications

    Children under 18 years
    Breastfeeding
    Catecholamine-secreting tumour
    Galactosaemia
    History of neuroleptic malignant syndrome
    History of non-traumatic rhabdomyolysis
    Pregnancy
    Severe hepatic impairment

    Precautions and Warnings

    Females of childbearing potential
    Patients over 85 years
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Moderate hepatic impairment

    Reduce dose in patients with moderate hepatic impairment
    Advise ability to drive/operate machinery may be affected by side effects
    Contains lactose
    Monitor liver function if anorexia,nausea,vomiting,abdominal pain develop
    Monitor patients for impulse control disorders
    Review treatment if impulse control disorders symptoms occur
    Female: Ensure adequate contraception during treatment
    Advise patient not to take two doses on the same day if a dose is missed
    Advise patient/carer about symptoms of impulse control disorders

    Pregnancy and Lactation

    Pregnancy

    Opicapone is contraindicated during pregnancy.

    The manufacturer does not recommend using opicapone during pregnancy. Animal studies have shown teratogenic effects. Human data is limited and as such a potential risk cannot be ruled out.

    Lactation

    Opicapone is contraindicated during breastfeeding.

    Use of opicapone when breastfeeding is contraindicated by the manufacturer. The presence of opicapone in human breast milk and the effects on exposed infants are unknown.

    Side Effects

    Abdominal distension
    Abdominal pain
    Anxiety
    Auditory hallucinations
    Chromaturia
    Constipation
    Creatine phosphokinase increased
    Decreased appetite
    Depression
    Dizziness
    Dream abnormalities
    Dry eyes
    Dry mouth
    Dysgeusia
    Dyskinesia
    Dyspepsia
    Dyspnoea
    Ear congestion
    Hallucinations
    Headache
    Hyperkinesia
    Hypertension
    Hypertriglyceridaemia
    Hypotension
    Insomnia
    Muscle spasm
    Muscle twitch
    Myalgia
    Nightmares
    Nocturia
    Orthostatic hypotension
    Painful extremities
    Palpitations
    Sleep disorders
    Somnolence
    Stiffness
    Syncope
    Upper abdominal pain
    Visual hallucinations
    Vomiting
    Weight loss

    Overdosage

    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Further Information

    Last Full Review Date: January 2020

    Reference Sources

    Summary of Product Characteristics: Ongentys 50mg hard capsules. Bile Pharm UK Ltd. Revised February 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.